Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(acetazolamide )
8,741 results
  • Pseudotumor cerebri in kaposiform lymphangiomatosis: a case report and pathogenetic hypothesis. [Journal Article]
  • CNChilds Nerv Syst 2018 Apr 13
  • Barceló-López C, López-Guerrero AL, … Martínez-Lage JF
  • CONCLUSIONS:  A network of intracranial lymphatics is presently being investigated. Neuroimaging excluded KLA infiltration of the skull and/or meninges, leaving as the most plausible explanation for the child's pseudotumor cerebri the existence of an increase in intracranial venous pressure by venous compression at the thorax. To our knowledge, our case constitutes the first report of pseudotumor cerebri occurring in the context of KLA.
  • Evaluating off-label uses of acetazolamide. [Review]
  • AJAm J Health Syst Pharm 2018 Apr 15; 75(8):524-531
  • Van Berkel MA, Elefritz JL
  • CONCLUSIONS: Acetazolamide is a carbonic anhydrase inhibitor typically used for indications including epilepsy, glaucoma, edema, and altitude sickness but it may be prescribed in hospitalized patients for off-label indications. It inhibits carbonic anhydrase, which leads to reduced hydrogen ion secretion in the proximal renal tubule, resulting in increased bicarbonate and cation excretion and causing urinary alkalization and diuresis. In addition, acetazolamide decreases the production of cerebrospinal fluid (CSF) and aqueous humor, reducing intracranial pressure (ICP) and intraocular pressure. This allows acetazolamide to be used for treatment of idiopathic intracranial hypertension and elevated ICP due to CSF leaks to avoid invasive procedures. It is a sulfonamide derivative, with dosages ranging from 250 to 4,000 mg daily divided every 6-12 hours. The plasma half-life is 4-8 hours, though the pharmacologic effects of acetazolamide last longer. Acetazolamide is highly protein bound and primarily eliminated by the kidneys, so administration should not be more frequent than every 12 hours if creatinine clearance is less than 50 mL/min. Limited literature exists describing the optimal patients to receive acetazolamide therapy.The potential benefits of acetazolamide include ventilator weaning for chronic obstructive pulmonary disease patients, avoidance of invasive procedures in patients with a CSF leak or elevated ICP, and prevention of high-dose methotrexate toxicity and contrast-induced nephropathy. Uncertainty remains regarding the selection of patients who would best benefit from acetazolamide use.
  • Coronary artery bypass surgery in patients with chronic brain hypoperfusion. [Journal Article]
  • JCJ Cardiovasc Surg (Torino) 2018 Apr 03
  • Imura H, Maruyama Y, … Nitta T
  • CONCLUSIONS: CABG can be performed at an acceptable risk in patients with brain hypoperfusion. However, these patients suffered high stroke incidence during the follow-up. It is therefore, important to identify those patients preoperatively to plan and implement an appropriate treatment regime.
New Search Next